Sanofi's Wayrilz Approved in the EU as First BTK Inhibitor for Immune Thrombocytopenia
Thursday, December 25, 2025
The European Commission has granted approval to Sanofi's Wayrilz (rilzabrutinib), marking it as the first Bruton's tyrosine kinase (BTK) inhibitor specifically for treating immune thrombocytopenia (ITP) in adult patients who are refractory to other therapies. This approval, announced on December 23, 2025, and effective as of December 24, 2025, represents a significant advancement in the European biopharma landscape, particularly for rare immune-mediated diseases. ITP is characterized by complex immune dysregulation leading to low platelet counts, increased bleeding risks, and diminished quality of life, affecting patients with symptoms ranging from bruising to potentially life-threatening intracranial hemorrhage.
Wayrilz operates through a novel mechanism of multi-immune modulation, targeting BTK expressed in B cells, macrophages, and other innate immune cells. This approach addresses underlying immune pathways more comprehensively than previous treatments. The approval stems from the pivotal LUNA 3 phase 3 study (NCT04562766), which enrolled 202 adults with persistent or chronic ITP. The study demonstrated statistically significant results: 23% of Wayrilz patients achieved a durable platelet response at week 25 compared to 0% in the placebo group (p<0.0001), with a faster time to first response (36 days vs. not reached) and longer duration (7 weeks vs. 0.7 weeks). Secondary outcomes included reduced rescue therapy use and improvements in quality of life, as measured by the Immune Thrombocytopenia Patient Assessment Questionnaire, showing a 10.6-point gain in the Wayrilz arm versus 2.3 points for placebo.
Brian Foard, Executive Vice President and Head of Specialty Care at Sanofi, emphasized the drug's differentiated action, stating it leverages Sanofi's deep immunology expertise to deliver innovative solutions for rare diseases. The therapy employs Sanofi's TAILORED COVALENCY® technology for selective BTK inhibition, minimizing off-target effects. This EU nod follows prior approvals in the US and UAE, with ongoing reviews in Japan and China. Wayrilz has also secured orphan drug designations in the EU, US, and Japan for ITP, alongside fast track and orphan statuses for other indications like warm autoimmune hemolytic anemia (wAIHA), IgG4-related disease (IgG4-RD), and sickle cell disease (SCD).
For pharma executives and manufacturers, this approval underscores shifting regulatory priorities in Europe toward precision therapies for rare diseases, potentially influencing R&D investments in BTK inhibitors and similar modalities. Sanofi's pipeline expansion highlights strategic commitments to immunology, with Wayrilz now positioned as a cornerstone in their specialty care portfolio. The LUNA 3 data, presented at the 66th American Society of Hematology meeting and published in Blood, provides robust evidence for clinical adoption, including sustained platelet counts ≥50,000/μL without rescue therapy, reduced bleeding scores via the Idiopathic Thrombocytopenic Purpura Bleeding Scale, and lower physical fatigue.
Looking ahead, adolescent studies are ongoing, broadening potential patient access. This development aligns with broader EU biopharma trends, incentivizing innovation amid regulatory reforms. Supply chain partners and biotech innovators should note Wayrilz's oral, reversible profile, easing manufacturing and distribution compared to injectables. For regulators and strategists, it exemplifies efficient CHMP review processes post-positive opinion. Sanofi, listed on Euronext and Nasdaq, continues its AI-powered R&D drive, chasing immune system breakthroughs. Forward-looking, while risks like regulatory delays and competition persist, Wayrilz strengthens Europe's competitive pharma sector, fostering partnerships in drug discovery and clinical development. This milestone not only enhances treatment paradigms but also signals robust market potential for BTK-targeted therapies in immunology.[2]
In the context of European pharma strategy, Wayrilz's approval bolsters Sanofi's position against competitors, potentially spurring biosimilar developments and generics in adjacent spaces. Executives monitoring clinical trials will find the LUNA 3 endpoints—primary proportion of responders at week 24, time to response, and duration—pivotal for benchmarking future studies. Technology providers in digital health can leverage real-world evidence from ITP management to integrate Wayrilz into IT platforms for patient monitoring. Overall, this fosters a more innovative, patient-centric ecosystem in EU life sciences, with implications for manufacturing scale-up and supply chain resilience.
